Jublia Patent Expiration

Jublia is a drug owned by Bausch Health Americas Inc. It is protected by 18 US drug patents filed from 2014 to 2024 out of which none have expired yet. Jublia's patents have been open to challenges since 06 June, 2018. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 25, 2035. Details of Jublia's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478601 Applicator
Apr, 2035

(10 years from now)

Active
US11654139 Anti-infective methods, compositions, and devices
Oct, 2034

(9 years from now)

Active
US9662394 Stabilized efinaconazole compositions
Oct, 2034

(9 years from now)

Active
US10864274 Stabilized efinaconazole formulations
Oct, 2034

(9 years from now)

Active
US10828293 Anti-infective methods, compositions, and devices
Oct, 2034

(9 years from now)

Active
US10342875 Stabilized efinaconazole compositions
Oct, 2034

(9 years from now)

Active
US9302009 Compositions and methods for treating diseases of the nail
Oct, 2030

(5 years from now)

Active
US8486978 Compositions and methods for treating diseases of the nail
Oct, 2030

(5 years from now)

Active
US9861698 Compositions and methods for treating diseases of the nail
Jul, 2030

(5 years from now)

Active
US10105444 Compositions and methods for treating diseases of the nail
Jul, 2030

(5 years from now)

Active
US8039494 Compositions and methods for treating diseases of the nail
Jul, 2030

(5 years from now)

Active
US9566272 Compositions and methods for treating diseases of the nail
Jan, 2028

(3 years from now)

Active
US10828369 Compositions and methods for treating diseases of the nail
Jan, 2028

(3 years from now)

Active
US11213519 Compositions and methods for treating diseases of the nail
Jan, 2028

(3 years from now)

Active
US9877955 Compositions and methods for treating diseases of the nail
Jan, 2028

(3 years from now)

Active
US11872218 Compositions and methods for treating diseases of the nail
Jan, 2028

(3 years from now)

Active
US10512640 Compositions and methods for treating diseases of the nail
Jan, 2028

(3 years from now)

Active
US7214506 Method for treating onychomycosis
Feb, 2026

(1 year, 3 months from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Jublia's patents.

Given below is the list of recent legal activities going on the following patents of Jublia.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 21 May, 2024 US10864274
Payment of Maintenance Fee, 4th Year, Large Entity 18 Apr, 2024 US10828293
Recordation of Patent Grant Mailed 16 Jan, 2024 US11872218
Patent eGrant Notification 16 Jan, 2024 US11872218
Recordation of Patent eGrant 16 Jan, 2024 US11872218
Patent Issue Date Used in PTA Calculation 16 Jan, 2024 US11872218
Email Notification 16 Jan, 2024 US11872218
Mail Patent eGrant Notification 16 Jan, 2024 US11872218
Email Notification 28 Dec, 2023 US11872218
Issue Notification Mailed 27 Dec, 2023 US11872218


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Jublia and ongoing litigations to help you estimate the early arrival of Jublia generic.

Jublia's Litigations

Jublia been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 12, 2017, against patent number US7214506. The petitioner Argentum Pharmaceuticals LLC et al., challenged the validity of this patent, with Kaken Pharmaceutical Co., Ltd. et al. as the respondent. Click below to track the latest information on how companies are challenging Jublia's patents.

Last updated on November 5, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7214506 November, 2016 FWD Entered
(06 Jun, 2018)
Kaken Pharmaceutical Co., Ltd. Acrux DDS Pty Ltd.
US7214506 May, 2017 Terminated-Settled
(13 Nov, 2017)
Kaken Pharmaceutical Co., Ltd. et al. Argentum Pharmaceuticals LLC et al.


FDA has granted some exclusivities to Jublia. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Jublia, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Jublia.

Exclusivity Information

Jublia holds 2 exclusivities. All of its exclusivities have expired in 2023. Details of Jublia's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 06, 2019
New Patient Population(NPP) Apr 27, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Jublia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Jublia's family patents as well as insights into ongoing legal events on those patents.

Jublia's Family Patents

Jublia has patent protection in a total of 24 countries. It's US patent count contributes only to 30.6% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Jublia.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Jublia's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 25, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Jublia Generic API suppliers:

Efinaconazole is the generic name for the brand Jublia. 6 different companies have already filed for the generic of Jublia, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Jublia's generic

How can I launch a generic of Jublia before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Jublia's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Jublia's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Jublia -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.1 06 Jun, 2018 19 16 Dec, 2020 02 Oct, 2034 Eligible





About Jublia

Jublia is a drug owned by Bausch Health Americas Inc. It is used for treating onychomycosis and tinea unguium. Jublia uses Efinaconazole as an active ingredient. Jublia was launched by Bausch in 2014.

Approval Date:

Jublia was approved by FDA for market use on 06 June, 2014.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Jublia is 06 June, 2014, its NCE-1 date is estimated to be 06 June, 2018.

Active Ingredient:

Jublia uses Efinaconazole as the active ingredient. Check out other Drugs and Companies using Efinaconazole ingredient

Treatment:

Jublia is used for treating onychomycosis and tinea unguium.

Dosage:

Jublia is available in solution form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
10% SOLUTION Prescription TOPICAL